Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode

Schizophrenia Research

Volumn 78, Issue 2-3, 2005, Pages 161-169

  Strakowski, Stephen M ^a   Johnson, Jacqueline L ^b   DelBello, Melissa P ^a   Hamer, Robert M ^b   Green, Alan I ^c,l   Tohen, Mauricio ^d,h   Lieberman, Jeffrey A ^b,e   Glick, Ira ^f   Patel, Jayendra K ^g   Lieberman, Jeffrey ⁱ   Perkins, Diana ⁱ   McEvoy, Joseph P ^j   Charles, Cecil ^j   Keefe, Richard ^j   Zipursky, Robert B ^k   Daskalakis, Zafiris J ^k   Nemeroff, Charles B ^m   Murray, Robin ⁿ   Sharma, Tonmoy ⁿ   Gur, Raquel E ^o   Cohen, Bruce ^h   Centorrino, Franca ^h   Kahn, R S ^p   Goodman, Wayne ^q   Kuldau, John ^q   Rothschild, Anthony J ^g   De Quardo, John ^r   Tollefson, Gary ^d   Sanger, Todd ^d   more..

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e New York Presbyterian Columbia University Medical Center   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^h MCLEAN HOSPITAL   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^k UNIVERSITY OF TORONTO   (Canada)

^l HARVARD MEDICAL SCHOOL   (United States)

^m EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ KING'S COLLEGE LONDON   (United Kingdom)

^o HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^p UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^q UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^r UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

more..

Author keywords

First episode psychosis; Functional outcome; Schizophrenia; SF 26

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SHORT FORM 36; SOCIAL STATUS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; PAIN; PAIN MEASUREMENT; PSYCHOTIC DISORDERS; QUALITY OF LIFE; TIME FACTORS;

EID: 24344477059     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.04.017     Document Type: Article

References (25)

1. A.G. Awad, and L.N. Voruganti New antipsychotics, compliance, quality of life, and subjective tolerability - are patients better off? Canadian Journal of Psychiatry 49 2004 283 284
2. H.E. Cannon-Spoor, S.G. Potkin, and R.J. Wyatt Measurement of premorbid adjustment in chronic schizophrenia Schizophrenia Bulletin 8 1982 470 484
3. M.B. First, R.L. Spitzer, M. Gibbon, and J.B.W. Williams Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Editions (SCID-I/P) 1995 Biometrics Research Department, New York State Psychiatric Institute 722 West 168th Street, New York, NY 10032
4. A.I. Green, M.F. Tohen, and R.M. Hamer First episode schizophrenia- related psychosis and substance use disorders: acute response to olanzapine and haloperidol Schizophrenia Research 66 2004 125 135
5. O. Gureje, W. Miles, and N. Keks Olanzapine vs. risperidone I the management of schizophrenia: randomized double-blind trial in Australia and New Zealand Schizophrenia Research 61 2003 303 314
6. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophrenia Bulletin 13 1987 261 276
7. R. Kilian, S. Dietrich, M. Toumi, and M.C. Angermeyer Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics Acta Psychiatrica Scandinavica 110 2004 108 118
8. J.A. Lieberman, B. Sheitman, and M. Chakos The development of treatment resistance in patients with schizophrenia: a clnical and pathophysiological perspective Journal of Clinical Psychopharmacology 18 1998 205 245
9. J. Lieberman, M. Tohen, and A.I. Green Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized double-blind trial of olanzapine vs. haloperidol American Journal of Psychiatry 160 2003 1396 1404
10. C.J. Meijer, A.H. Schene, and M.W. Koeter Quality of life in schizophrenia measured by the MOS SF-36 and lancashire quality of life profile: a comparison Acta Psychiatrica Scandinavica 105 2002 293 300
11. H.J. Moller Management of the negative symptoms of schizophrenia: new treatment options CNS Drugs 17 2003 793 823
12. D. Naber, M. Riedel, and A. Klimke Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia Acta Psychiatrica Scandinavica 111 2005 106 115
13. H.A. Nasrallah, I. Duchesne, A. Mehnert, C. Janagap, and M. Eerdekens Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone Journal of Clinical Psychiatry 65 2004 531 536
14. Perkins, D.O., Johnson, J.L., Hamer, R.M., et al., submitted for publication. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
15. D. Perkins, J. Lieberman, and H. Gu Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders British Journal of Psychiatry 185 2004 18 24
16. R. Pukrop, V. Schlaak, and A.M. Möller-Leimkühler Reliability and validity of quality of life assessed by the short-form 36 and the modular system for quality of life in patients with schizophrenia and patients with depression Psychiatry Research 119 2003 63 79
17. D.A. Revicki, L.A. Genduso, and S.H. Hamilton Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial Quality of Life Research 8 1999 417 426
18. M. Ritsner, A. Gibel, G. Perelroyzen, R. Kurs, M. Jabarin, and Y. Ratner Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study Journal of Clinical Psychopharmacology 24 2004 582 591
19. R. Rosenheck, D. Perlick, and D. Bingham Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial Journal of the American Medical Association 290 2003 2693 2702
20. J. Russo, C.A. Trujillo, and D. Wingerson The MOS 36-item short form healthy survey: reliability, validity and preliminary findings in schizophrenic outpatients Medical Care 36 1998 752 756
21. T. Sharma, and L. Antonova Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment Psychiatric Clinics of North America 26 2003 25 40
22. S.M. Strakowski Diagnostic validity of schizophreniform disorder American Journal of Psychiatry 151 1994 815 824
23. S.L. Tunis, T.W. Croghan, D.K. Heliman, B.M. Johnstone, and R.L. Obenchain Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol Medical Care 37 1999 678 691
24. J.E. Ware, K.K. Snow, M. Kosinski, and B. Gandek SF-36 Health Survey Manual and Interpretation Guide 1993 The Health Institute, New England Medical Center Boston, MA
25. J.E. Ware, M. Koskinsk, and S.D. Keller SF-36 Physical and Mental Health Summary Scales: A User's Manual 1994 The Health Institute, New England Medical Center Boston, MA